Table 2.
Treatment for extremity soft tissue sarcoma patients
| Treatment | Age | n (%) | OR (95 % CI) | p | Adjusted OR (95 % CI) | p* |
|---|---|---|---|---|---|---|
| No treatment | <0.001 | <0.001 | ||||
| <65 | 50 (2.7) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 13 (4.5) | 1.7 (0.9–3.2) | 1.6 (0.8–3.1) | |||
| 70–74 | 24 (8.8) | 3.5 (2.1–5.8) | 3.2 (1.8–5.6) | |||
| 75–79 | 15 (5.6) | 2.2 (1.2–3.9) | 1.7 (0.9–3.3) | |||
| 80–84 | 28 (13.7) | 5.8 (3.6–9.4) | 5.6 (3.2–9.6) | |||
| 85+ | 27 (16.2) | 7.0 (4.3–11.6) | 8.3 (4.7–14.6) | |||
| Surgery (monotherapy) | 0.002 | 0.0003 | ||||
| <65 | 787 (42.1) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 105 (36.6) | 0.8 (0.6–1.0) | 0.8 (0.6–1.0) | |||
| 70–74 | 93 (34.2) | 0.7 (0.5–0.9) | 0.7 (0.5–0.9) | |||
| 75–79 | 121 (45.5) | 1.1 (0.9–1.5) | 1.2 (0.9–1.6) | |||
| 80–84 | 82 (40.2) | 0.9 (0.7–1.2) | 0.9 (0.7–1.3) | |||
| 85+ | 88 (52.7) | 1.5 (1.1–2.1) | 1.7 (1.2–2.3) | |||
| Radiotherapy (monotherapy) | <0.001 | 0.0003 | ||||
| <65 | 13 (0.7) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 4 (1.4) | 2.0 (0.7–6.2) | 2.0 (0.6–6.2) | |||
| 70–74 | 5 (1.8) | 2.7 (0.9–7.6) | 2.4 (0.8–7.0) | |||
| 75–79 | 12 (4.5) | 6.7 (3.0–15.0) | 6.3 (2.7–14.8) | |||
| 80–84 | 9 (4.4) | 6.6 (2.8–15.6) | 6.1 (2.4–15.1) | |||
| 85+ | 3 (1.8) | 2.6 (0.7–9.3) | 2.4 (0.7–9.0) | |||
| Chemotherapy (monotherapy) | 0.4 | 0.2 | ||||
| <65 | 74 (4.0) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 13 (4.5) | 1.2 (0.6–2.1) | 1.1 (0.6–2.2) | |||
| 70–74 | 14 (5.2) | 1.3 (0.7–2.4) | 1.2 (0.7–2.4) | |||
| 75–79 | 7 (2.6) | 0.7 (0.3–1.4) | 0.5 (0.2–1.2) | |||
| 80–84 | 4 (2.0) | 0.5 (0.2–1.3) | 0.4 (0.1–1.1) | |||
| 85+ | 4 (2.4) | 0.6 (0.2–1.6) | 0.7 (0.2–2.0) | |||
| Surgery and chemotherapy | 0.06 | 0.08 | ||||
| <65 | 96 (5.1) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 16 (5.6) | 1.1 (0.6–1.9) | 1.1 (0.6–2.0) | |||
| 70–74 | 8 (2.9) | 0.6 (0.3–1.2) | 0.6 (0.3–1.2) | |||
| 75–79 | 5 (1.9) | 0.4 (0.1–0.9) | 0.4 (0.1–0.9) | |||
| 80–84 | 6 (2.9) | 0.6 (0.2–1.3) | 0.5 (0.2–1.3) | |||
| 85+ | 0 (0.0) | – | – | |||
| Surgery and radiotherapy | 0.004 | 0.0005 | ||||
| <65 | 739 (39.5) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 124 (43.2) | 1.2 (0.9–1.5) | 1.2 (1.0–1.6) | |||
| 70–74 | 124 (45.6) | 1.3 (1.0–1.6) | 1.4 (1.1–1.9) | |||
| 75–79 | 102 (38.4) | 1.0 (0.7–1.2) | 1.0 (0.7–1.3) | |||
| 80–84 | 74 (36.3) | 0.9 (0.6–1.2) | 0.9 (0.7–1.3) | |||
| 85+ | 45 (27.0) | 0.6 (0.4–0.8) | 0.5 (0.4–0.8) | |||
| Surgery and radiotherapy and chemotherapy | 0.001 | 0.003 | ||||
| <65 | 96 (5.1) | 1.0 (ref) | 1.0 (ref) | |||
| 65–69 | 10 (3.5) | 0.7 (0.4–1.3) | 0.7 (0.3–1.3) | |||
| 70–74 | 4 (1.5) | 0.3 (0.1–0.8) | 0.3 (0.1–0.8) | |||
| 75–79 | 4 (1.5) | 0.3 (0.1–0.8) | 0.3 (0.1–0.8) | |||
| 80–84 | 1 (0.5) | 0.1 (0.01–0.7) | 0.1 (0.01–0.7) | |||
| 85+ | 0 (0.0) | – | – |
Chemotherapy and radiotherapy: 15 patients <65 years and two patients aged 65–69 years
Ref reference category
* p value adjusted for sex, year, grade, stage, and type of sarcoma